Category: Markets
Published: 2026-07-16T11:54:17.000Z
Moderna has initiated a Phase 1 study by dosing the first U.S. patient with mRNA-4200, an investigational cancer therapy for advanced or metastatic solid tumors. This therapy, developed in collaboration with Immatics, encodes seven common cancer antigens and will be evaluated for safety and tolerability in combination with checkpoint inhibitor therapy. The news comes amid other significant developments for Moderna, including advancements in its autoimmune disease and influenza vaccine programs, and a raised price target from Piper Sandler.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.